Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells
Introduction
Drug resistance constitutes a major obstacle to successful chemotherapy in cancer patients. One of the common forms of resistance to chemotherapy is caused by activation of the MDR1 (ABCB1) gene, resulting in overexpression of P-glycoprotein (P-gp), a 170–190 kDa transmembrane glycoprotein that belongs to the ATP-binding cassette superfamily and acts as a multidrug transporter [1]. Overexpression of P-gp confers cancer cell resistance to a broad range of structurally and functionally diverse chemotherapeutic drugs [2]. Multidrug resistance (MDR) mediated by the overexpression of MDR1/P-gp can be intrinsic, or induced by a variety of chemical and physical insults such as cytotoxic agents, arsenite, heat shock, and UV irradiation [3], [4], [5], [6], [7], [8], and the transcriptional activation of the MDR1 gene is a highly regulated complex event and is associated with several signaling pathways. For example, our laboratory demonstrated that activation of the phospholipase C/Raf/mitogen-activated protein kinase pathway stimulates the transcription of the MDR1 gene and expression of P-gp, and this pathway can be activated by heat shock, platelet-derived growth factor (PDGF) and epidermal growth factor (EGF) [9]. We also showed that the activation of the MDR1 gene transcription requires involvement of a number of transcriptional factors such as C-terminal-binding protein 1 (CtBP1) [10]. Nevertheless, the precise mechanism(s) underlying the activation of MDR1 gene expression is still not fully understood. We previously reported the inhibitory effect of small interfering RNA (siRNA) on MDR1/P-gp expression and the feasibility of using RNA interference (RNAi) approach to modulate MDR phenotype [11]. These studies have led to a better understanding of the regulation of the expression of MDR1 gene, and have helped to develop new strategies to inhibit or prevent the induction of MDR1/P-gp expression. To further understand the roles of small RNA molecules in the regulation of drug resistance genes, we investigated the involvement of microRNAs (miRNA) in controlling MDR phenotype mediated by MDR1/P-gp. MiRNAs are a class of endogenous, 19–25 nucleotides RNA molecules that are able to induce mRNA degradation, translational repression, or both, via pairing with partially complementary sites in the 3′ UTR of the targeted genes [12]. It is estimated that there are over 600 miRNAs in mammalian cells, and that 30% of all genes are regulated by miRNAs. Because miRNAs have the ability to target numerous mRNAs, these small RNA molecules can operate highly complex regulatory networks and regulate the expression of genes in many pathways that are associated with tumor initiation, development and progression. Through regulating gene expression, miRNAs can have a profound impact on many patho-physiologic processes, including proliferation, apoptosis, and stress response [13], [14]. In the current study, we observed that miRNAs were differentially expressed in MDR cancer cells, and demonstrated that expressions of miRNA 27a and 451 are associated with the activation of MDR1/P-gp expression and contribute to drug resistance in cancer cells.
Section snippets
Cell culture and reagents
Human ovarian cancer cell line, A2780, and its multidrug resistant counterpart, A2780DX5, were kindly supplied by Dr. Youcef Rustum (Roswell Park Cancer Institute, Buffalo, NY). Human cervix carcinoma cell line KB-3-1 and its MDR variant KB-V1 were kindly provided by Dr. Michael M. Gottesman (National Cancer Institute, Bethesda, MD). These cell lines were routinely maintained in Dulbecco's modified Eagle's medium (Invitrogen Life Technologies, Gaithersburg, MD) containing 10% (v/v) fetal bovine
Results and discussion
To explore the roles of miRNAs in MDR phenotype, we first compared the profiling of miRNA expression between the human MDR cancer cells and their parental drug sensitive cells. Using a miRNA microarray (OSUCCC-microRNA version 4.0), we observed a differential expression pattern between the MDR cells and parental cells. As shown in Table 1, the expressions of miR-27a, miR-99a, miR-100, miR-125b1 and miR-451 were increased (2.0–7.8-fold) in human MDR ovarian cancer cell line A2780DX5 and cervix
Acknowledgement
This study was supported by US Public Health Service grants NCI CA 66077 and CA 72720.
References (24)
- et al.
The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research
FEBS Lett
(2006) - et al.
Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells
J Biol Chem
(1990) - et al.
Transcriptional activation of the MDR1 gene by UV irradiation. Role of NF-Y and Sp1
J Biol Chem
(2000) - et al.
Involvement of CtBP1 in the transcriptional activation of the MDR1 gene in human multidrug resistant cancer cells
Biochem Pharmacol
(2007) - et al.
A developmental view of microRNA function
Trends Biochem Sci
(2007) MicroRNAs: genomics, biogenesis, mechanism, and function
Cell
(2004)MicroRNAs in vertebrate development
Curr Opin Genet Dev
(2005)- et al.
Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver
Biochem Pharmacol
(2005) - et al.
Suppression of P-glycoprotein gene expression in Hs578T/Dox by the overexpression of caveolin-1
FEBS Lett
(2004) - et al.
Evidence for binding of extrachromosomal DNA sequences to nuclear matrix proteins in multidrug-resistant KB-V1 cells
FEBS Lett
(1993)
The role of ABC transporters in clinical practice
Oncologist
Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin
Clin Cancer Res
Cited by (419)
Melodic maestros: Unraveling the role of miRNAs in the diagnosis, progression, and drug resistance of malignant pleural mesothelioma
2023, Pathology Research and PracticeDoxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming
2023, Molecular Aspects of MedicineDrug–MicroRNA Cross-Talk
2023, MicroRNA in Regenerative Medicine, Second EditionRegulation of P-glycoprotein by miR-27a-3p at the Brain Endothelial Barrier
2022, Journal of Pharmaceutical Sciences
- 1
H. Zhu and H. Wu contributed equally to this study.